No Data
No Data
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025
Phathom Spikes as Cantor Fitzgerald Bullish on IP Claims
$PHAT Stock Is up 7% Today. Here's What We See in Our Data.
Cantor Fitzgerald Initiates Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Announces Target Price $23
Phathom Pharmaceuticals Initiated at Cantor Fitzgerald on 'Significant' Upside
Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target